Gamco Investors INC. ET AL cut its holdings in shares of C.R. Bard, Inc. (NYSE:BCR) by 53.2% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,800 shares of the medical instruments supplier’s stock after selling 16,792 shares during the period. Gamco Investors INC. ET AL’s holdings in C.R. Bard were worth $4,743,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Creative Planning boosted its holdings in C.R. Bard by 24.0% in the second quarter. Creative Planning now owns 5,331 shares of the medical instruments supplier’s stock valued at $1,685,000 after purchasing an additional 1,033 shares during the last quarter. National Pension Service boosted its holdings in C.R. Bard by 25.1% in the second quarter. National Pension Service now owns 74,873 shares of the medical instruments supplier’s stock valued at $23,577,000 after purchasing an additional 15,009 shares during the last quarter. Chevy Chase Trust Holdings Inc. boosted its holdings in C.R. Bard by 0.3% in the second quarter. Chevy Chase Trust Holdings Inc. now owns 62,879 shares of the medical instruments supplier’s stock valued at $19,877,000 after purchasing an additional 216 shares during the last quarter. Chesley Taft & Associates LLC purchased a new stake in C.R. Bard in the second quarter valued at $248,000. Finally, Meeder Asset Management Inc. boosted its holdings in C.R. Bard by 78.9% in the second quarter. Meeder Asset Management Inc. now owns 10,484 shares of the medical instruments supplier’s stock valued at $3,314,000 after purchasing an additional 4,623 shares during the last quarter. 79.04% of the stock is currently owned by institutional investors and hedge funds.

C.R. Bard, Inc. (BCR) opened at $331.89 on Friday. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.57. The firm has a market cap of $24,192.13, a P/E ratio of 28.66, a P/E/G ratio of 2.54 and a beta of 0.53. C.R. Bard, Inc. has a 1 year low of $203.63 and a 1 year high of $335.84.

C.R. Bard (NYSE:BCR) last issued its quarterly earnings results on Wednesday, October 25th. The medical instruments supplier reported $3.02 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.96 by $0.06. C.R. Bard had a net margin of 14.75% and a return on equity of 48.28%. The company had revenue of $989.80 million during the quarter, compared to analysts’ expectations of $990.64 million. During the same quarter last year, the company posted $2.64 EPS. The firm’s revenue was up 5.1% compared to the same quarter last year. analysts expect that C.R. Bard, Inc. will post 11.89 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, December 29th. Shareholders of record on Friday, December 8th will be given a $0.26 dividend. The ex-dividend date is Thursday, December 7th. This represents a $1.04 annualized dividend and a yield of 0.31%. C.R. Bard’s dividend payout ratio is presently 13.70%.

Several research firms have recently issued reports on BCR. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a research note on Monday, July 31st. Jefferies Group LLC reissued a “hold” rating on shares of C.R. Bard in a research note on Thursday, August 3rd. BidaskClub lowered shares of C.R. Bard from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Barclays PLC increased their target price on shares of C.R. Bard from $245.00 to $337.00 and gave the stock an “equal weight” rating in a research note on Monday, November 6th. Finally, Needham & Company LLC reissued a “hold” rating on shares of C.R. Bard in a research note on Thursday, October 26th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $303.50.

In other news, insider Sharon M. Luboff sold 30,252 shares of the firm’s stock in a transaction on Friday, September 29th. The shares were sold at an average price of $320.00, for a total value of $9,680,640.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Timothy P. Collins sold 8,388 shares of the firm’s stock in a transaction on Monday, October 9th. The shares were sold at an average price of $322.00, for a total transaction of $2,700,936.00. The disclosure for this sale can be found here. Insiders sold a total of 191,593 shares of company stock valued at $62,655,513 in the last three months. 0.80% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This story was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this story can be accessed at https://www.watchlistnews.com/gamco-investors-inc-et-al-sells-16792-shares-of-c-r-bard-inc-bcr/1697659.html.

C.R. Bard Company Profile

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Want to see what other hedge funds are holding BCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for C.R. Bard, Inc. (NYSE:BCR).

Institutional Ownership by Quarter for C.R. Bard (NYSE:BCR)

Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.